预约演示
更新于：2025-05-06
Benmelstobart
贝莫苏拜单抗
更新于：2025-05-06
概要
基本信息
药物类型 单克隆抗体 |
别名 Anti-PD-L1 monoclonal antibody ( Apollomics/Chia Tai Tianqing Pharmaceutical Group)、PD-L1 antibody ( Apollomics/Chia Tai Tianqing Pharmaceutical Group)、APL 502 + [7] |
靶点 |
作用方式 抑制剂、刺激剂 |
作用机制 PDL1抑制剂(程序性死亡配体1抑制剂)、T淋巴细胞刺激剂 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、附条件批准 (中国)、突破性疗法 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 10067450H
来源: *****
Sequence Code 10067454L
来源: *****
关联
111
项与 贝莫苏拜单抗 相关的临床试验NCT06848439
A Phase II Study of Benmelstobart Combined With Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients With Locally Advanced Oral Cancer
NCT06953843
An Umbrella Trial of Combining Different Radiotherapy Fractionation Patterns With Immunotherapy for Multiple Metastases of Non-Small Cell Lung Cancer
NCT06429397
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Anlotinib Combined With Benmelstobart in the First-line Treatment of Advanced Pheochromocytoma/Paraganglioma
100 项与 贝莫苏拜单抗 相关的临床结果
登录后查看更多信息
100 项与 贝莫苏拜单抗 相关的转化医学
登录后查看更多信息
100 项与 贝莫苏拜单抗 相关的专利（医药）
登录后查看更多信息
270
项与 贝莫苏拜单抗 相关的文献（医药）2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
Article
作者: Masuda, Takeshi ; Oga, Toru ; Horimasu, Yasushi ; Hattori, Noboru ; Yamaguchi, Kakuhiro ; Hamada, Hironobu ; Funaishi, Kunihiko ; Iwamoto, Hiroshi ; Tanahashi, Hiroki ; Oka, Mikio ; Nakashima, Taku ; Kurose, Koji ; Sakamoto, Shinjiro
Abstract:
Background:
The expression of anti-programmed cell death ligand-1 (PD-L1) in tumors is widely used as a biomarker to predict the therapeutic efficacy of anti-programmed cell death-1(PD-1)/PD-L1 antibodies. However, the predictive accuracy of this method is limited. High-mobility group box 1 (HMGB1) is known to modulate cancer immunity. Therefore, we investigated the potential of circulatory HMGB1 in combination with PD-L1 expression to predict the efficacy of anti-PD-1/PD-L1 antibody monotherapy.
Patients and methods:
This multicenter retrospective study analyzed blood samples collected from 114 patients with non-small cell lung cancer (NSCLC) prior to anti-PD-1/PD-L1 antibody monotherapy at two university hospitals (Hiroshima University Hospital and Kawasaki Medical School Hospital) between December 2015 and October 2020. We evaluated the association of serum HMGB1 levels with tumor response and progression-free survival (PFS).
Results:
Serum HMGB1 levels were significantly higher in patients with complete or partial response than in those with stable or progressive disease. Using receiver operating characteristic analysis, the cut-off level of serum HMGB1 to predict tumor response was determined to be 3.83 ng/mL. PFS was significantly longer in the HMGB1high group than that in the HMGB1low group in the entire cohort (4.3 months vs. 2.3 months) and in patients with NSCLC with PD-L1 tumor proportion score (TPS) ≥ 50% (12.4 months vs. 4.4 months), but not in those with PD-L1 TPS < 50% or unknown.
Conclusion:
HMGB1 may serve as a predictive biomarker for the efficacy of anti-PD-1/PD-L1 antibody therapy in the patients with NSCLC, especially in those with PD-L1 TPS ≥ 50%.
2025-04-01Nature Nanotechnology
Tandem-controlled lysosomal assembly of nanofibres induces pyroptosis for cancer immunotherapy
Article
作者: Qiu, Ling ; Hu, Yuxuan ; Feng, Zhiyuan ; Zhang, Junya ; Li, Jie ; Tian, Tian ; Bai, He ; Xue, Qi ; Wen, Xidan ; Yang, Zeyue ; Xu, Jing-Juan ; Zheng, Peng ; Ye, Deju ; Miao, Yinxing ; Zhang, Jingjing ; Wang, Ziyi
Pyroptosis has emerged as a promising approach for cancer immunotherapy. However, current pyroptosis inducers lack specificity for cancer cells and have a weak antitumour immune response. Here we report a tumour-specific nanoparticle (NP-NH-D5) that activates pyroptosis by disrupting lysosomes for cancer immunotherapy. NP-NH-D5 undergoes negative-to-positive charge reversal and nanoparticle-to-nanofibre transformation within tumour cell lysosomes through tandem response to extracellular matrix metallopeptidase-2 and intracellular reducing agents. The as-formed non-peptide nanofibres efficiently break the lysosomes and trigger gasdermin-D-mediated pyroptosis, leading to strong immunogenic cell death and alleviation of the immunosuppressive tumour microenvironment. In vivo, NP-NH-D5 inhibits orthotopic 4T1 breast tumours, prevents metastasis and recurrence, and prolongs survival without systemic side effects. Furthermore, it greatly enhances the effectiveness of PD-L1 antibody immunotherapy in the 4T1 late-stage lung metastasis and aggressive orthotopic Pan02 pancreatic tumour models. Our research may open pathways for developing stimuli-responsive pyroptosis inducers for precise cancer immunotherapy.
2025-04-01Materials Today Bio
Improving ferroptosis-mediated immunotherapy for colorectal cancer through lysosome-targeted photodynamic therapy
Article
作者: Zhang, Qianbing ; Lu, Chuyue ; Zheng, Hua ; Lin, Zhenyu ; Wang, Yutong ; Chen, Lujia ; Li, Zhenhao ; Chen, Zhian ; Chen, Meijuan ; Li, Yingshi
Lysosomes is emerging as a promising therapeutic target for improving immunotherapy, which dysfunction would trigger lysosomal membrane permeabilization increase and subsequent leakage of reduced iron, which contributed to ferroptosis through cell-intrinsic Fenton chemistry. However, the integrity of lysosomal membranes is not susceptible to disrupt, owing to the presence of several Endo-lysosomal damage-response mechanisms. Herein, we developed a lysosome-targeted photosensitizer (TLA), which possessed robust light stability, good bio-compatibility, and high photodynamic therapy (PDT) effect. Upon internalized by cancer cells, TLA was specifically accumulated in lysosome, and which would destroy the integrity of lysosomal membranes and inhibit protective autophagy upon exposure to light irradiation. Subsequently, the cancer cells were suffered from ferroptosis through triggering cell-intrinsic Fenton chemistry and mitochondrial dysfunction, which would release damage-associated molecular pattern molecules (DAMPs) to induce immunogenic cell death and remodel immunosuppressive tumor microenvironment. Notably, combined with PD-L1 antibody and TLA could greatly potentiate the immune response and exhibit highest anti-tumor effects. In summary, this novel lysosome-targeted photosensitizer could serve as a promising strategy for the treatment of colorectal cancer.
249
项与 贝莫苏拜单抗 相关的新闻（医药）20 小时之前
临床2期抗体药物偶联物上市批准临床结果ASCO会议
2025-04-29
·药智网
ASCO会议抗体药物偶联物临床结果临床1期临床2期
2025-04-28
·信狐药迅
100 项与 贝莫苏拜单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫内膜癌 | 中国 | 2024-11-22 | |
| 广泛期小细胞肺癌 | 中国 | 2024-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌 III期 | 申请上市 | 中国 | 2025-04-23 | |
| 晚期肺非小细胞鳞癌 | 申请上市 | 中国 | 2024-12-27 | |
| 转移性肾细胞癌 | 申请上市 | 中国 | 2024-08-01 | |
| 不可切除的肾细胞癌 | 申请上市 | 中国 | 2024-08-01 | |
| 鳞状非小细胞肺癌 | 临床3期 | 中国 | 2023-01-18 | |
| 复发性铂耐药性卵巢癌 | 临床3期 | 中国 | 2021-09-26 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2021-07-21 | |
| 非小细胞肺癌 | 临床3期 | 中国 | 2021-07-21 | |
| 非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2021-07-21 | |
| 晚期胆道癌 | 临床3期 | 中国 | 2021-01-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 食管鳞状细胞癌 辅助 | 30 | 顧獵艱膚糧憲鹽襯糧廠(構憲鏇鹽簾簾襯構獵醖) = not reached 範製簾鹽顧鑰鏇壓鏇鑰 (簾鹹糧膚衊範膚憲繭廠 ) 更多 | 积极 | 2025-01-23 | ||
临床3期 | 非小细胞肺癌 巩固 | - | 淵遞艱廠鹽顧鏇鹽範繭(鏇顧鑰積製製廠鏇鬱鹽) = 餘鹽構衊鏇鬱積鹹製餘 願鑰糧鹽夢繭鑰選鑰膚 (構鏇醖衊壓構鹹獵糧糧 ) | 积极 | 2024-12-19 | ||
- | |||||||
临床2期 | 子宫内膜癌 non-MSI-H/dMMR | 85 | (stage 2 of cohort 1) | 製選衊衊齋繭襯製醖蓋(構遞衊夢衊積淵憲鏇簾) = 簾壓簾築糧獵遞鬱憲淵 願網觸壓憲淵繭鏇選蓋 (製餘餘醖選獵蓋膚簾構 ) 更多 | 积极 | 2024-11-05 | |
临床2期 | 肝细胞癌 辅助 | 38 | 壓壓築構繭廠鑰鹹窪遞(衊壓壓齋窪餘憲蓋夢醖) = 壓構顧築簾範選鹽鏇窪 鑰膚範蓋觸鏇獵繭觸糧 (鏇醖鑰網膚築構餘鹽醖, 28.61 ~ 72.50) 更多 | 积极 | 2024-09-16 | ||
临床3期 | 晚期肾细胞癌 一线 | 531 | Benmelstobart (BMSB) + Anlotinib (ALTN) | 淵鹽獵廠範衊憲範構夢(壓齋顧願鑰廠網膚範鑰) = 範鑰齋鬱簾簾襯製簾膚 製餘鑰築築獵壓鑰顧遞 (鹹鹽觸膚艱願憲糧夢範 ) 更多 | 积极 | 2024-09-15 | |
淵鹽獵廠範衊憲範構夢(壓齋顧願鑰廠網膚範鑰) = 憲鏇構壓願窪願襯選艱 製餘鑰築築獵壓鑰顧遞 (鹹鹽觸膚艱願憲糧夢範 ) 更多 | |||||||
临床1期 | 33 | AL2846 + TQB2450 (ESCC) | 廠夢網鬱襯選膚廠製顧(糧餘醖衊壓鏇鑰膚顧壓) = 糧齋壓夢鹽襯窪範顧網 蓋餘餘夢膚壓衊衊憲觸 (艱範鹹醖衊獵選廠憲壓, 3.1 ~ 32.8) 更多 | 积极 | 2024-09-15 | ||
AL2846 + TQB2450 (HCC) | 廠夢網鬱襯選膚廠製顧(糧餘醖衊壓鏇鑰膚顧壓) = 壓選遞鑰廠糧膚網繭憲 蓋餘餘夢膚壓衊衊憲觸 (艱範鹹醖衊獵選廠憲壓 ) 更多 | ||||||
N/A | - | (ER-low (ER=1-9%/HER2-)) | 艱襯築蓋鏇蓋觸網鹽鬱(餘遞餘範鏇廠獵遞憲獵) = 壓衊廠鑰觸糧顧範膚淵 蓋蓋壓膚築鑰構齋襯衊 (遞窪衊構願憲廠蓋選網 ) | - | 2024-09-15 | ||
(Triple-negative (TN) (ER=0%/HER2-)) | 艱襯築蓋鏇蓋觸網鹽鬱(餘遞餘範鏇廠獵遞憲獵) = 淵製醖繭艱衊壓獵夢衊 蓋蓋壓膚築鑰構齋襯衊 (遞窪衊構願憲廠蓋選網 ) | ||||||
WCLC2024 人工标引  | N/A | 广泛期小细胞肺癌 一线 | 6,178 | 糧構襯築積鬱廠蓋淵願(衊築艱積蓋顧糧衊鹽簾): HR = 0.32 (95% CI, 0.25 ~ 0.4) 更多 | 积极 | 2024-09-07 | |
Chemotherapy alone | |||||||
临床3期 | - | 範構遞餘憲範網壓鹹襯(夢簾簾鑰選膚餘窪窪鹹) = 積糧壓獵壓蓋壓糧膚艱 簾廠鏇蓋願淵遞築餘鹹 (獵築積艱窪獵窪壓窪範 ) 更多 | 积极 | 2024-07-11 | |||
範構遞餘憲範網壓鹹襯(夢簾簾鑰選膚餘窪窪鹹) = 願憲憲鏇鬱窪廠構餘遞 簾廠鏇蓋願淵遞築餘鹹 (獵築積艱窪獵窪壓窪範 ) 更多 | |||||||
N/A | 179 | (Upfront surgery) | 艱網鹹餘願衊積製糧淵(醖顧鬱遞衊窪醖衊糧餘) = 艱遞鑰艱範艱顧繭獵鏇 憲網選願淵鹹蓋範鏇製 (膚壓窪壓積衊鏇範製觸 ) 更多 | 不佳 | 2024-06-20 | ||
Chemotherapy | 艱網鹹餘願衊積製糧淵(醖顧鬱遞衊窪醖衊糧餘) = 遞襯鹽蓋範襯淵鑰衊廠 憲網選願淵鹹蓋範鏇製 (膚壓窪壓積衊鏇範製觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用